

Edgar Filing: EPIX MEDICAL INC - Form S-8

EPIX MEDICAL INC
Form S-8
August 02, 2002

As filed with the Securities and Exchange Commission on August 2, 2002

REGISTRATION NO. 333-_____

=====

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

EPIX MEDICAL, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

DELAWARE
(STATE OR OTHER JURISDICTION
OF INCORPORATION OR ORGANIZATION)

04-3030815
(I.R.S. EMPLOYER
IDENTIFICATION NO.)

71 ROGERS STREET
CAMBRIDGE, MASSACHUSETTS 02142
(617) 250-6000
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)

EPIX MEDICAL, INC. AMENDED AND RESTATED 1992 EQUITY INCENTIVE PLAN

MICHAEL D. WEBB, CHIEF EXECUTIVE OFFICER
EPIX MEDICAL, INC.
71 ROGERS STREET
CAMBRIDGE, MASSACHUSETTS 02142
(617) 250-6000
(NAME, ADDRESS, INCLUDING ZIP CODE, AND TELEPHONE NUMBER, INCLUDING AREA
CODE, OF AGENT FOR SERVICE)

with copies to:

William T. Whelan, Esquire
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
One Financial Center
Boston, Massachusetts 02111
(617) 542-6000

CALCULATION OF REGISTRATION FEE

=====

Title of securities to be registered	Amount to be Registered (1)	Proposed Maximum Offering Price	Proposed Maximum Aggregate
--------------------------------------	-----------------------------	---------------------------------	----------------------------

Edgar Filing: EPIX MEDICAL INC - Form S-8

		Per Share (2)	Offering Price (2)
Common Stock, \$.01 par value	500,000	\$4.32	\$2,160,000

- (1) The number of shares of common stock, par value \$.01 per share ("Common Stock"), stated above consists of the aggregate number of shares which may be sold upon exercise of options which have been granted and/or may hereafter be granted under the EPIX Medical, Inc. Amended and Restated 1992 Equity Incentive Plan (the "Option Plan"). The maximum number of shares which may be sold upon exercise of options granted under the Option Plan is subject to adjustment in accordance with certain anti-dilution and other provisions of such Plan. Accordingly, pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement covers, in addition to the number of shares stated above, an indeterminate number of shares which may be subject to grant or otherwise issuable after the operation of any such anti-dilution and other provisions.
- (2) This calculation is made solely for the purpose of determining the registration fee pursuant to the provisions of Rule 457(h) under the Securities Act. The fee is calculated on the basis of the average of the high and low sale prices per share of the Common Stock on the Nasdaq National Market as of a date (July 30, 2002) within 5 business days prior to filing this Registration Statement.

EXPLANATORY NOTE

The content of the Registration Statement on Form S-8 (File No. 333-30531) of EPIX Medical, Inc. is hereby incorporated by reference. The purpose of this Form S-8 is to reflect an increase in the number of shares authorized for issuance under the Amended and Restated 1992 Equity Incentive Plan.

Exhibits.

- 5.1 Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. as to the legality of shares being registered
- 23.1 Consent of Ernst & Young LLP

1

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Cambridge, Massachusetts on August 2, 2002.

EPIX MEDICAL, INC.

Edgar Filing: EPIX MEDICAL INC - Form S-8

By: /s/ Michael D. Webb

Michael D. Webb
Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

SIGNATURE	TITLE	DATE
/s/ Michael D. Webb ----- Michael D. Webb	Chief Executive Officer and Director (Principal Executive Officer)	August
/s/ Pamela E. Carey ----- Pamela E. Carey	Vice President of Finance and Administration and Chief Financial Officer	August
/s/ Christopher F. O. Gabrieli ----- Christopher F. O. Gabrieli	Chairman of the Board and Director	August
/s/ Stanley T. Crooke ----- Stanley T. Crooke, M.D., Ph.D.	Director	August
/s/ Peter Wirth ----- Peter Wirth	Director	August
/s/ Randall B. Lauffer ----- Randall B. Lauffer, Ph.D.	Director	August